ライフサイエンスコーパス: adjuvant therapy

1 an increased risk of metastasis and may need adjuvant therapy.

2 nagement of the primary and neck tumors, and adjuvant therapy.

3 apy/CCRT PET/CT scan within 1 wk of starting adjuvant therapy.

4 ereas those with high GC scores benefit from adjuvant therapy.

5 ns, HBOT may be considered as an alternative adjuvant therapy.

6 se stage II patients who better benefit from adjuvant therapy.

7 sis of breast cancer was referred to discuss adjuvant therapy.

8 djusting for age, stage of disease, and (neo)adjuvant therapy.

9 es, suggesting a role for cancer vaccines as adjuvant therapy.

10 cebo (1:1:1) for the duration of trastuzumab adjuvant therapy.

11 r no optic nerve involvement and received no adjuvant therapy.

12 nt benefit are needed to inform colon cancer adjuvant therapy.

13 ltration can be surgically targeted prior to adjuvant therapy.

14 A total of 438 (85.9%) received adjuvant therapy.

15 eptic ulcer bleeding has been recommended as adjuvant therapy.

16 nd patients received neither neoadjuvant nor adjuvant therapy.

17 ative breast cancer as a chemotherapeutic or adjuvant therapy.

18 mprove upon the existing standard of care in adjuvant therapy.

19 ce were associated with early termination of adjuvant therapy.

20 nces were observed in patients not receiving adjuvant therapy.

21 the role of IHC in identifying patients for adjuvant therapy.

22 in (FOLFOX) has been the standard of care in adjuvant therapy.

23 rgery or on pathology; 31.8% (2168) received adjuvant therapy.

24 % CI, 0.62-1.23) after adjusting for age and adjuvant therapy.

25 current definition of disease risk and guide adjuvant therapy.

26 vasion; blood transfusion; and postoperative adjuvant therapy.

27 d muscle-specific microRNAs offer promise as adjuvant therapy.

28 ide a more tailored approach to colon cancer adjuvant therapy.

29 oving the selection of stage II patients for adjuvant therapy.

30 ts who would receive additional benefit from adjuvant therapy.

31 as definitive therapy or as a postoperative adjuvant therapy.

32 vascular disease, histological diagnosis and adjuvant therapy.

33 vant chemoradiation, surgical resection, and adjuvant therapy.

34 ct to studies and protocols on patients with adjuvant therapy.

35 with improved survival when compared with no adjuvant therapy.

36 drug is approved as either a monotherapy or adjuvant therapy.

37 colon cancer during the first 3 years after adjuvant therapy.

38 ial enrollment, metastatic surveillance, and adjuvant therapy.

39 al (OS) could expedite the evaluation of new adjuvant therapies.

40 sk stratification, and select candidates for adjuvant therapies.

41 criteria for randomized trials investigating adjuvant therapies.

42 these patients for the application of novel adjuvant therapies.

43 avenue of investigation for the delivery of adjuvant therapies.

44 nt selection is mandatory for neoadjuvant or adjuvant therapies.

45 ion are urgently needed to investigate novel adjuvant therapies.

46 herefore needed to evaluate various systemic adjuvant therapies.

47 the cause of genetic diseases and to suggest adjuvant therapies.

48 and surgical approaches accompanied by novel adjuvant therapies.

49 n be treated by surgery alone rather than by adjuvant therapies.

50 uld be incorporated into decisions regarding adjuvant therapies.

51 increasing the antigen dose, and the use of adjuvant therapies.

52 stem to better target patients for trials of adjuvant therapies.

53 dentify patients who may benefit from future adjuvant therapies.

54 roved survival and a reduction in subsequent adjuvant therapies.

55 rgical extirpation and reliance on effective adjuvant therapies.

56 rapy (23.3 months) than cholecystectomy with adjuvant therapy (16.4 months), which was significantly

57 mab (41.9 per 100 patients) compared with no adjuvant therapy (18.1 per 100 patients, p < 0.001).

58 tly longer for extended cholecystectomy with adjuvant therapy (23.3 months) than cholecystectomy with

59 mated groups had at least 3 years of planned adjuvant therapy (36.1% vs 65.9%; P < .001).

60 t routinely indicated; (3) consideration for adjuvant therapy; (4) further clinical trials; (5) multi

61 g patients at high risk for recurrence after adjuvant therapy, a group that may benefit from VEGFR-2

62 of postoperative complications on the use of adjuvant therapy after colectomy for cancer.

63 Data on optimal adjuvant therapy after complete resection of small-cell

64 Thirty percent of patients discontinued adjuvant therapy after less than 3 months.

65 cavity squamous cell carcinoma who received adjuvant therapy after radical surgery were included.

66 ients with BC with similar ER, nodal status, adjuvant therapy, age, and year of diagnosis.

67 itis are likely to be multidimensional, with adjuvant therapies aimed at modifying the immune respons

68 Adjuvant therapies aimed at reducing the immune response

69 ay readmission, 30-day mortality, and use of adjuvant therapies (all P > 0.05).

70 There is no known effective adjuvant therapy, although various combinations have bee

71 Adverse outcomes can be minimized by adjuvant therapies and 'no touch' techniques at the time

72 e) in view of directing patients properly to adjuvant therapies and consecutively evaluate both progn

73 investigated the relationship between these adjuvant therapies and subclinical cerebral small-vessel

74 als were grouped considering neoadjuvant and adjuvant therapies and surgery alone, neoadjuvant therap

75 e-negative patients who received no systemic adjuvant therapy and 259 tamoxifen-treated patients.

76 ifferent preparations of beta-glucans in the adjuvant therapy and allow for the rational design of im

77 ts requiring additional treatments and delay adjuvant therapy and are associated with worse prognoses

78 patients and guide recommendations regarding adjuvant therapy and postoperative surveillance of patie

79 se patients may benefit from more aggressive adjuvant therapy and postoperative surveillance regimens

80 Patients were stratified by previous adjuvant therapy and randomly assigned (1:1) via a rando

81 n of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate

82 to select patients who may benefit from neo-adjuvant therapy and to avoid overtreatment in those pat

83 e risk offers the potential to individualize adjuvant therapy and to minimize long-term adverse effec

84 bjectives were tolerability, compliance with adjuvant therapy, and biomarker distribution.

85 ariable models that also included sex, prior adjuvant therapy, and BRAF mutational status.

86 Perioperative morbidity, use of adjuvant therapy, and long-term survival were examined a

87 d (center, number of metastatic sites, prior adjuvant therapy, and measurable cancer) and randomly as

88 Imaging studies, surgical approach, adjuvant therapy, and pathology reports were reviewed.

89 gic data were correlated with clinical data, adjuvant therapy, and patient outcome.

90 Simple cholecystectomy with adjuvant therapy appears to be superior to extended rese

91 ssive screening or alternative approaches to adjuvant therapy are needed.

92 Hence, relationships to cancer, surgery, and adjuvant therapy are unclear.

93 vantage compared with total laryngectomy and adjuvant therapy as indicated.

94 The benefit of adjuvant therapy (AT) for biliary tract cancer (BTC) is

95 nosis, it should be done after completion of adjuvant therapy (before 1 year).

96 Adjuvant therapy benefit analyses were limited to the ni

97 We examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and

98 In trials demonstrating adjuvant therapy benefit, similar DFS benefit was observ

99 II and III colon cancer had similar RFI and adjuvant therapy benefit.

100 Adjuvant therapy can be done to reduce the risk of recur

101 three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumour

102 ive no benefit from fluorouracil (FU) -based adjuvant therapy compared with patients who have microsa

103 and consistent use both during and following adjuvant therapy conferred no benefit.

104 To assess if simple cholecystectomy with adjuvant therapy could provide outcomes comparable to ex

105 radiotherapy, total mesorectal excision, and adjuvant therapy) currently applied to all patients with

106 lining influence of axillary nodal status on adjuvant therapy decision-making, ongoing clinical trial

107 into the clinical context may better inform adjuvant therapy decisions in stage III as well as stage

108 tumor biology are increasingly used to make adjuvant therapy decisions.

109 Use of adjuvant therapy declined with age and comorbidity.

110 eated by primary enucleation with or without adjuvant therapy depending on histopathologic risk facto

111 ric location, which had an impact on planned adjuvant therapy duration.

112 ondrion-targeted ROS scavengers as potential adjuvant therapies during severe infections.

113 Adjuvant therapy followed national standards.

114 between 1987 and 2010, either primarily, as adjuvant therapy following incomplete resection, or as s

115 cell lines may be useful for discovering new adjuvant therapies for aggressive thyroid cancers.

116 us therapeutics for deployment as primary or adjuvant therapies for epidermal disorders.

117 tant cancer prevention strategies as well as adjuvant therapies for improving outcomes.

118 ne key strategy for developing host-directed adjuvant therapies for tuberculosis (TB).

119 sectability rate 71%), of which 26 initiated adjuvant therapy for a total of 23 patients (60.5%) who

120 AC inhibitors might find therapeutic use as adjuvant therapy for advanced melanoma.

121 be warranted in the use of curcumin, even as adjuvant therapy for CNS lupus.

122 C and this approach might be promising as co-adjuvant therapy for cystic fibrosis.

123 e and noninvasiveness makes HOT an appealing adjuvant therapy for diabetes prevention and interventio

124 chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer.

125 Several studies have demonstrated that adjuvant therapy for high-risk melanoma patients with IF

126 As adjuvant therapy for high-risk stage III melanoma, ipili

127 intergroup trials E1684, E1690, and E1694 as adjuvant therapy for high-risk surgically resected melan

128 ials may be further explored as an effective adjuvant therapy for infected bone defects and/or osteom

129 Purpose Adjuvant therapy for intermediate-risk and high-risk loc

130 etionary for men receiving either primary or adjuvant therapy for localized but high-grade tumors.

131 vaccines have had a record of failure as an adjuvant therapy for malignancies that are treated with

132 tus for survival outcome after resection and adjuvant therapy for pancreatic cancer.

133 sphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer.

134 We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected s

135 There is no standard of care for adjuvant therapy for patients with hepatocellular carcin

136 e data support the consideration of Bumex as adjuvant therapy for patients with high-grade gliomas.

137 the US Food and Drug Administration-approved adjuvant therapy for patients with high-risk melanoma.

138 s setting and should not be considered as an adjuvant therapy for patients with resected early-stage

139 s fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for patients with stage III colon cance

140 erapeutic potential of mPGES-1 inhibitors as adjuvant therapy for percutaneous coronary intervention.

141 of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two

142 uld be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor-pos

143 dronate (1,600 mg/d orally) be considered as adjuvant therapy for postmenopausal patients with breast

144 trial comparing letrozole with tamoxifen as adjuvant therapy for postmenopausal women with hormone r

145 ety of anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-s

146 ical trials to take the next step forward in adjuvant therapy for prostate cancer because of the exce

147 CXL used as adjuvant therapy for recalcitrant deep stromal fungal ke

148 e standard care with compression therapy and adjuvant therapy for refractory wounds, at present in cl

149 se of 1 mg in a standard practice setting as adjuvant therapy for resected early breast cancer.

150 il, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer.

151 Trastuzumab is a key component of adjuvant therapy for stage I to III human epidermal grow

152 tentially curative surgery and completion of adjuvant therapy for stage II and III CRC were randomly

153 hylactic cranial irradiation, relative to no adjuvant therapy for stage T1-2N0M0 SCLC.

154 trate the potential of Rev3 inhibition as an adjuvant therapy for the treatment of chemoresistant mal

155 verteporfin should be further explored as an adjuvant therapy for the treatment of glioblastoma.

156 tudies are underway to determine the optimal adjuvant therapy for these tumors.

157 present a promising and more tissue-specific adjuvant therapy for this disease.

158 f high-grade gliomas and may be an effective adjuvant therapy for this disease.

159 rticle, Se supplementation is proposed as an adjuvant therapy for treatment of chronic Chagas disease

160 Prospects for clinical studies of systemic adjuvant therapy for uveal melanoma are enhanced by mult

161 of patient and disease factors in selecting adjuvant therapy for women with early-stage breast cance

162 a subgroup of UR patients who also received adjuvant therapy-for early-stage resectable pancreatic a

163 disagreement regarding its use vs. selective adjuvant therapy, given the modest benefits seen with cu

164 American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell l

165 Adjuvant therapy had a tendency to correlate significant

166 with complete surgical resection and minimal adjuvant therapy have been shown to have excellent outco

167 ight not receive the recommended duration of adjuvant therapy if their risk of recurrence is underest

168 Patients were excluded if 5-FU was used as adjuvant therapy, if they did not complete therapy, or i

169 In R1 patients adjuvant therapy improved survival and reduced distant r

170 Adding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients

171 present a valid strategy for neuroprotective adjuvant therapies in HAND.

172 Using adiponectin for adjuvant therapies in iron-overload cardiac dysfunction

173 whether such immunological markers may guide adjuvant therapies in stage III metastatic melanomas.

174 tial role for selenium supplementation as an adjuvant therapy in CML.

175 nstrate that CXCR7 is a potential target for adjuvant therapy in combination with androgen deprivatio

176 ble E2 delivery platform shows promise as an adjuvant therapy in craniofacial care of patients.

177 thereby highlighting its putative role as an adjuvant therapy in defined GBM patient populations.

178 hat glucagon antagonism could i) be a useful adjuvant therapy in diabetes only when residual insulin

179 DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer.

180 rovide similar rates of remnant ablation and adjuvant therapy in low and intermediate risk patients w

181 e dose, and high dose have been evaluated as adjuvant therapy in melanoma.

182 induced osteolysis and may be valuable as an adjuvant therapy in OSCC to preserve mandibular and maxi

183 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-posit

184 cy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcino

185 (HDI) has emerged as a potentially effective adjuvant therapy in patients with resected melanoma at h

186 Decisions regarding adjuvant therapy in patients with stage II colorectal ca

187 ion of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and

188 atic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers

189 indicating prednisolone may be an effective adjuvant therapy in some cases of DCK-negative AML.

190 ion may provide a more tailored approach for adjuvant therapy in stage II colon cancer.

191 ical data related to the benefit of FU-based adjuvant therapy in such patients.

192 tation (HSCT) and infusion of CAR T cells as adjuvant therapy in the autologous (n = 7) or allogeneic

193 sed in conjunction with opioids and standard adjuvant therapy in the management of chronic uncontroll

194 s indicate that PACK-CXL may be an effective adjuvant therapy in the management of severe infectious

195 mphangiogenesis inhibitor, as a potential co-adjuvant therapy in the treatment of AML.

196 tus should help determine who should receive adjuvant therapy in this select subset of patients.

197 isease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast canc

198 Limited data exist regarding the outcomes of adjuvant therapy in younger patients with stage II and I

199 ion of oxaliplatin to fluoropyrimidine-based adjuvant therapy increased during the study period (P tr

200 Current carcinoma treatments include adjuvant therapy intended to kill the cryptic metastatic

201 ndent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal ar

202 Adjuvant therapy is beneficial for colon cancer in patie

203 However, the use of adjuvant therapy is increasing.

204 he utility of disease-staging modalities and adjuvant therapy is needed.

205 The delivery of postoperative adjuvant therapy is problematic in this disease because

206 Adjuvant therapy is recommended for high-risk patients w

207 referred choice or for high-risk cases where adjuvant therapy is recommended.

208 Oxaliplatin-based adjuvant therapy is the standard of care for stage III c

209 owing surgery to determine whether immediate adjuvant therapy is warranted.

210 Adjuvant therapies may improve the outcome, but clinical

211 ermore, these studies suggest that effective adjuvant therapies may need to target the CSC population

212 ally identifying subgroups with the need for adjuvant therapy may be possible.

213 If GTR is not achieved, adjuvant therapy might delay tumour progression or recur

214 ed with a subset of UR patients who received adjuvant therapy, NAT patients had a better survival (ad

215 For making decisions regarding adjuvant therapy, nodal status, tumor size, estrogen rec

216 Molecular adjuvant therapy of AD animal models with glatiramer ace

217 Institutes of Health Consensus Conference on Adjuvant Therapy of Breast Cancer recommended chemothera

218 ation has a limited but relevant role in the adjuvant therapy of gastric cancer (GC) patients.

219 s and, hence, as a potential drug target for adjuvant therapy of solid tumors.

220 ctions of the incremental effects of EOR and adjuvant therapy on survival.

221 er risk of recurrence who would benefit from adjuvant therapies or more frequent surveillance, thereb

222 ing patients who may benefit from aggressive adjuvant therapy or stratifying patients for adjuvant cl

223 alterations confer a favourable response to adjuvant therapy, or which signalling pathways might be

224 ns increased the likelihood of not receiving adjuvant therapy over twofold [odds ratio (OR) = 2.20, 9

225 Adjuvant therapy prolongs survival after resection of T2

226 ial surgical site infection did not decrease adjuvant therapy receipt but delayed the time to its use

227 t further consideration: tumor histology and adjuvant therapy recommendations, risk stratification to

228 s the primary consideration in breast cancer adjuvant therapy recommendations.

229 nts with residual tumour who did not receive adjuvant therapy, recurrence occurred early and Ki-67 LI

230 nefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age.

231 tial AC-T is likely to be the most effective adjuvant therapy regimen for early-stage breast cancer r

232 ork meta-analysis to test the most effective adjuvant therapy regimen in terms of overall survival (O

233 r Data Base from 2003 to 2011, stratified by adjuvant therapy regimen, was evaluated using Kaplan-Mei

234 tiple-relapse patients receiving LMP-CTLs as adjuvant therapy remained in remission at a median of 3.

235 Optimal duration of adjuvant therapy remains undefined.

236 dioactive iodine (RAI) is routinely used for adjuvant therapy, remnant ablation, and for the treatmen

237 ion regret, prognostication test result, and adjuvant therapy, respectively, while adjusting for age

238 many years after primary tumor resection and adjuvant therapy seems to arise from tumor cells that di

239 dequacy of surgical staging should influence adjuvant therapy selection in the United States.

240 Postoperative adjuvant therapy should be considered in patients with h

241 5% CI 0.76-0.90), whereas surgery along with adjuvant therapies showed no significant survival advant

242 alysis of interaction between MMR status and adjuvant therapy showed a trend toward improved progress

243 Adjuvant therapy significantly improved DFS (hazard rati

244 Adjuvant therapy significantly improved survival in pati

245 tion of patients insufficiently treated with adjuvant therapy so they can be offered secondary adjuva

246 tic tumors might be promising tools to study adjuvant therapy strategies for patients.

247 t, including 57% of patients who received no adjuvant therapy, suggesting that chemotherapy could be

248 ho lack HER2 amplification, may benefit from adjuvant therapy that targets HER2.

249 In the context of adjuvant therapy, the resection margin status remains an

250 develop better-tolerated chemotherapies and adjuvant therapies to prevent anorexia and concurrent nu

251 reclinical evaluation of novel multimodal or adjuvant therapies to prevent recurrence and metastasis

252 Evidence for the use of various prophylactic adjuvant therapies to prevent vasospasm, including magne

253 lts suggest that fidarestat could be used as adjuvant therapy to enhance DOX sensitivity of CRC cells

254 against CoV M(pro) through using zinc as an adjuvant therapy to enhance the efficacy of an irreversi

255 memory functions and FTY720 may be a useful adjuvant therapy to facilitate extinction of aversive me

256 tive cancer vaccines can offer a much needed adjuvant therapy to fill the treatment gap after liver r

257 ement definitive therapy with either neo- or adjuvant therapy to improve prognosis.

258 , could increase patient survival if used as adjuvant therapy to inhibit both the early colonization

259 client protein, SF3B2 may be developed as an adjuvant therapy to prevent neurotoxicity in cisplatin-b

260 vailable Mac-1 (CD11b/CD18) antibodies as an adjuvant therapy to radiotherapy.

261 erefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patien

262 gest that CCR5 antagonists may be used as an adjuvant therapy to reduce the risk of metastasis in pat

263 ven after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast canc

264 ent counseling and selection of patients for adjuvant therapy trials.

265 rrently integrated into prognostic models or adjuvant therapy trials.

266 es, craniotomy, corticosteroids as a main or adjuvant therapy, use of drains, irrigation of the hemat

267 Adjuvant therapy using anti-GD2 monoclonal antibody and

268 Patients who received adjuvant therapy versus surgery alone were more likely t

269 ntrolled trials reporting on neoadjuvant and adjuvant therapies was conducted.

270 Adjuvant therapy was administered to 59% of patients (n

271 Adjuvant therapy was defined as chemotherapy, with or wi

272 Adjuvant therapy was less frequently started in older pa

273 Management by excisional biopsy followed by adjuvant therapy was successful, and histopathology and

274 one propensity score matching for receipt of adjuvant therapy was used to account for potential selec

275 by recombinant human IFN-gamma (rhIFN-gamma) adjuvant therapy, we investigated macrophage functions f

276 Adjuvant therapies were given after primary tumor resect

277 Incisional biopsy and excision without adjuvant therapy were associated with a poor outcome in

278 eatment or within 12 months of completion of adjuvant therapy-were randomly assigned (2:1) via a cent

279 e breast cancer who did not receive systemic adjuvant therapy, when adjusted for common pathology par

280 pecially poorly defined in terms of need for adjuvant therapies, which can be associated with both sh

281 ut tumor progression, possibly influenced by adjuvant therapies, which significantly influences survi

282 spectively enrolled in a randomized trial of adjuvant therapy with a whole-cell melanoma vaccine, Can

283 Adjuvant therapy with an aromatase inhibitor improves ou

284 o are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxife

285 reast cancers can be successfully treated by adjuvant therapy with antiestrogens or aromatase inhibit

286 sitive eBC were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anast

287 l, 353 patients with colon cancer undergoing adjuvant therapy with FOLFOX (fluorouracil, leucovorin,

288 ein had the longest survival times following adjuvant therapy with gemcitabine.

289 Adjuvant therapy with imatinib benefits patients with a

290 Adjuvant therapy with imatinib mesylate improves recurre

291 Adjuvant therapy with imatinib prolongs recurrence-free

292 Patients with colon cancer undergoing adjuvant therapy with infusional fluorouracil, leucovori

293 At the 5-year follow-up, 1 year of extended adjuvant therapy with neratinib, administered after chem

294 such therapy was improbable), appropriate as adjuvant therapy with radiation therapy for men with loc

295 recurrence rate, within the first 2 years of adjuvant therapy with some benefit in years 3 to 4, tran

296 to justify a clinical trial of breast cancer adjuvant therapy with statins and we advocate for such a

297 addition of ovarian suppression to standard adjuvant therapy with tamoxifen or with an aromatase inh

298 colon cancer recurrence and mortality after adjuvant therapy with these newer options.

299 elated with poor long-term outcome following adjuvant therapy with trastuzumab.

300 ith zoledronic acid, in addition to standard adjuvant therapy, would improve disease outcomes in such